StoneX Group’s Decoy Therapeutics DCOY Stock Holding History

StoneX Group’s Portfolio DCOY Stock Details DCOY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,666	Closed	-$13K	–	1205
2025 Q4	$13K	Buy	+1,666	New	+$43.2K	﹤0.01%	990

Other funds holding DCOY

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

StoneX Group's DCOY Position: Q1 2026 in Review

StoneX Group sold out of Decoy Therapeutics (DCOY) in Q1 2026, closing a stake of 1,666 shares — an estimated $13K sold.

StoneX Group first reported a position in DCOY in Q4 2025 and held it in 1 quarter. The position peaked at $13K in Q4 2025. 4 funds tracked by Wall St. Rank hold DCOY as of Q1 2026.

StoneX Group reported no remaining Decoy Therapeutics position as of Q1 2026 after selling out during the quarter.
StoneX Group sold 1,666 Decoy Therapeutics shares in Q1 2026, an estimated $13K.
StoneX Group first reported a position in Decoy Therapeutics in Q4 2025 and held it in 1 quarter.
StoneX Group's Decoy Therapeutics position peaked at $13K in Q4 2025.
4 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.